Market
Will Eli Lilly's obesity drug surpass CagriSema in market share by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from reputable financial analysis firms
Story
Novo Nordisk Shares Drop 27% as CagriSema Misses Weight Loss Target in Phase 3 Trial
Dec 20, 2024, 11:00 AM
Novo Nordisk, Europe's largest company, saw its shares plummet by up to 27%, marking its worst trading day since April 2002, after its experimental obesity drug CagriSema failed to meet weight loss expectations in the Phase 3 REDEFINE 1 trial. The trial showed that patients treated with CagriSema achieved a 22.7% weight reduction after 68 weeks, falling short of the anticipated 25%. Additionally, only 57% of patients reached the highest dose after 68 weeks. Comparatively, patients receiving semaglutide 2.4 mg and cagrilintide 2.4 mg experienced weight losses of 16.1% and 11.8%, respectively, while the placebo group lost 2.3%. The disappointing results led to a significant sell-off, with the stock losing its 200-day moving average at $125 and trading 48% below its June high. Competitors such as Eli Lilly and Viking Therapeutics saw their shares rise in response to the news.
View original story
Similar markets
No • 50%
Yes • 50%
Novo Nordisk 40-60% • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk • 33%
Eli Lilly • 33%
Another competitor • 34%
20% to 30% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
No • 50%
Yes • 50%
Zepbound • 25%
Other • 25%
Saxenda • 25%
Wegovy • 25%
No • 50%
Yes • 50%
Outside top 5 • 25%
Leader in the sector • 25%
Top 5 in the sector • 25%
Top 3 in the sector • 25%